Company Overview and News

Soho China, Ltd. 2018 Q2 - Results - Earnings Call Slides

2018-08-17 seekingalpha
The following slide deck was published by Soho China, Ltd. in conjunction with their 2018 Q2 earnings call.
SOHOF 0410

China has consolidated property ownership data, but to levy tax is a separate struggle

2018-06-26 scmp
Beijing’s 10-year debate on implementing a property tax and the shift from a 2019 deadline to complete legislation to an indefinite one are signs of entailed difficulty and hesitation
SOHOF 0410

Co-working space operator Soho China targets Hong Kong IPO next year as it expands in the mainland

2018-06-20 scmp
Soho China, one of the country’s largest commercial property companies, aims to list its co-working space business in Hong Kong next year, according to its chairman Pan Shiyi.
SOHOF 3968 0410

Blackstone plans to step up buying in Asia after raising US$9.4bil

The New York-based alternative asset manager will have US$15bil to deploy to real estate, private equity and other opportunities in Asia once money from its global funds is included, according to Jonathan Gray, Blackstone’s president and chief operating officer.

Five Hong Kong-listed Chinese property developers to see big rises in 2017 profit

2018-03-25 scmp
Surging property sales and rising margins will lift profits, though the effect of property market curbs adds a note of uncertainty

Chinese developers report strong profits but credit curbs could spell trouble

2018-03-20 scmp
Mainland property developers have posted strong earnings for 2017, but liquidity remains a concern as Beijing keeps a tight lid on financing to cool the housing market.

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...